ASCO 2025 | Mitigating irAEs in GU cancers requires a multidisciplinary approach
Chiara Mercinelli, MD, IRCCS San Raffaele Hospital, Milan, Italy, discusses how to mitigate immune-related adverse effects (irAEs) in genitourinary (GU) cancers, saying they require a proactive, multidisciplinary approach through the collaboration with specialists such as dermatologists. This allows for earlier recognition and initiation of corticosteroid treatment for effective irAE management, preventing escalation into higher-grade toxicity and allowing the continuation of treatment. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The key of course is a multidisciplinary approach because I’m lucky because I work in a very big hospital in Milan and every time we have something that looks like immune-related toxicity we have a strong network with dermatologists, rheumatologists and all the other specialties so we have a good connection with them, starting as soon as possible corticosteroids, so trying to avoid having higher grades of toxicity in order to manage them as soon as possible...
The key of course is a multidisciplinary approach because I’m lucky because I work in a very big hospital in Milan and every time we have something that looks like immune-related toxicity we have a strong network with dermatologists, rheumatologists and all the other specialties so we have a good connection with them, starting as soon as possible corticosteroids, so trying to avoid having higher grades of toxicity in order to manage them as soon as possible.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Travel, Accommodations, Expenses – Johnson & Johnson/Janssen
